Photo of Dan G. Duda,

Dan G. Duda

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 726-4648
Fax: (617) 726-1962


duda@steele.mgh.harvard.edu

Dan G. Duda

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Radiation Oncology, Harvard Medical School
  • Associate Biologist, Radiation Oncology, Steele Laboratory, Massachusetts General Hospital

Research Abstract

My areas of expertise are 1) the biology of local-derived stroma (tumor-associated vessels, fibroblasts) and distant stroma (bone marrow-derived cells or BMDCs) in tumor progression; and 2) the development of predictive biomarkers for targeted therapies for cancer. I aim to translate this knowledge into improved therapies by conducting preclinical and clinical studies in collaboration with MGH clinicians.

I am currently leading the following projects:

1. Overcoming Evasion from Sorafenib Treatment in Hepatocellular Carcinoma (HCC)

Sorafenib is the first systemic therapy approved for HCC. However, HCC rapidly evade sorafenib treatment, despite its multi-targeted activities. We are studying the pathways of evasion from sorafenib in HCC (P01/PPG Project 3). We are examining the role of MEK/ERK activation as a cell autonomous mechanism of escape. We are also studying how sorafenib-induced changes in HCC stroma lead to stromal-derived growth factor 1 alpha (SDF1alpha/CXCL12)-mediated changes in vascular structure and function, inflammation/bone marrow-derived cell infiltration and fibrosis, and if these mediate HCC escape from treatment. To this end, we have developed orthotopic models of metastatic HCC in immunocompetent mice, and have developed and acquired spontaneous genetically engineered mouse models of HCC through our collaborations at MGH Cancer Center. In parallel, we are exploring the potential roles of stroma-derived factors in HCC patients treated with sorafenib and other antiangiogenic agents in collaboration with Dr. Zhu of the MGH Cancer Center.

2. Impact of Tumor Stroma Activation after Radiation Therapy on Local Tumor Control and Metastasis

We have found that SDF1alpha/CXCR4 and HGF/cMET pathways can be activated by ionizing radiation in tumor stroma. Thus, we are currently evaluating the role of SDF1alpha/CXCR4 or HGF/cMET inhibition as a sensitizer for radiation therapy in preclinical models. Specifically, we are examining 1) the role of SDF1alpha and its receptors CXCR4 and CXCR7 in progression to metastasis after local radiotherapy (supported by an R01 grant); 2) the role of CXCR4 and bone marrow-derived cells in bone metastatic escape from palliative radiotherapy (funded through an ACS grant); and 3) the role of cMET inhibition in combination with radiotherapy in metastatic pancreatic adenocarcinoma models (supported by a Cummings Foundation grant). To this end, we have developed orthotopic models of prostate cancer, including a calvarial tumor model, which allows intravital microscopy imaging as well as orthotopic models of pancreatic adenocarcinoma. In parallel, we are exploring the potential roles of SDF1alpha/CXCR4 and HGF/cMET in prostate carcinoma, pancreatic adenocarcinoma, and HCC patients treated with radiotherapy in collaboration with MGH Cancer Center clinicians Drs. Efstathiou, Zhu and Hong (funded through NCI/Proton Beam Federal Share Program grants).

3. Biomarkers of Treatment Response

This project is carried out in the context of a large effort of clinical correlative studies (in over 25 clinical trials of antiangiogenic agents and/or radiotherapy), which include imaging, tissue and blood biomarker studies. This involves large teams of clinicians at MGH and Dana Farber Cancer Institute, and is funded through multiple collaborative grants from the NCI, DoD and NFCR. We are primarily focusing on the potential predictive biomarker value of soluble vascular endothelial growth factor (VEGF) receptor 1 (sVEGFR1 or sFLT1) and pharmacodynamics biomarker value of PlGF and sVEGFR2, and on the potential role of SDF1alpha and HGF as biomarkers of escape from anti-VEGF therapies or from radiotherapy.

Teaching:

I am teaching experimental techniques through daily supervision of postdoctoral research fellows, and graduate and undergraduate students. In the past ten years, I have been teaching in the MIT-HMS/HST Program, MGH-Chinese Oncologist Visiting Program, and ASTRO, ESTRO, RTOG and IASGO translational meetings for residents and clinicians, and in the yearly Methods in Bioengineering course that I am directing since 2002.

Publications

Powered by Harvard Catalyst
  • Jeong HS, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, Willett CG, Jain RK, Padera TP. Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. Journal of the National Cancer Institute 2015. PubMed
  • Goyal L, Chong DQ, Duda DG, Zhu AX. Chemotherapy and antiangiogenics in biliary tract cancer. Lancet Oncol. 2015. PubMed
  • Lemon CM, Karnas E, Han X, Bruns OT, Kempa TJ, Fukumura D, Bawendi MG, Jain RK, Duda DG, Nocera DG. Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors. J Am Chem Soc 2015. PubMed
  • Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. 2015. PubMed
  • Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res 2015. PubMed
  • Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 2015; 33:1197-213. PubMed
  • Hayano K, Tian F, Kambadakone AR, Yoon SS, Duda DG, Ganeshan B, Sahani DV. Texture Analysis of Non-Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma. J Comput Assist Tomogr 2015. PubMed
  • Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A 2015; 112:1547-52. PubMed
  • Han HS, Niemeyer E, Huang Y, Kamoun WS, Martin JD, Bhaumik J, Chen Y, Roberge S, Cui J, Martin MR, Fukumura D, Jain RK, Bawendi MG, Duda DG. Quantum dot/antibody conjugates for in vivo cytometric imaging in mice. Proc Natl Acad Sci U S A 2015; 112:1350-5. PubMed
  • Kambadakone A, Yoon SS, Kim TM, Karl DL, Duda DG, DeLaney TF, Sahani DV. CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression. AJR Am J Roentgenol 2014; 204:W11-8. PubMed
  • Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 2015. PubMed
  • Richter C, Seco J, Hong TS, Duda DG, Bortfeld T. Radiation-induced changes in hepatocyte-specific Gd-EOB-DTPA enhanced MRI: Potential mechanism. Med Hypotheses 2014; 83:477-81. PubMed
  • Duda DG, Ancukiewicz M, Isakoff SJ, Krop IE, Jain RK. Seeds and soil: unraveling the role of local tumor stroma in distant metastasis. Journal of the National Cancer Institute 2014. PubMed
  • Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology 2014. PubMed
  • Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG. A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Int J Radiat Oncol Biol Phys 2014. PubMed
  • Cucu D, Chiritoiu G, Petrescu S, Babes A, Stanica L, Duda DG, Horii A, Dima SO, Popescu I. Characterization of Functional Transient Receptor Potential Melastatin 8 Channels in Human Pancreatic Ductal Adenocarcinoma Cells. Pancreas 2014. PubMed
  • Stroh M, Duda DG, Takimoto CH, Yamazaki S, Vicini P. Translation of anticancer efficacy from nonclinical models to the clinic. CPT Pharmacometrics Syst Pharmacol 2014; 3:e128. PubMed
  • Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK. Benefits of vascular normalization are dose and time dependent--letter. Cancer Res 2013; 73:7144-6. PubMed
  • Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 2013; 110:19059-64. PubMed
  • Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG. Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1留/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice. Hepatology 2013. PubMed
  • Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K. A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clin Cancer Res 2013. PubMed
  • Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 2013. PubMed
  • Goel S, Gupta N, Walcott BP, Snuderl M, Kesler CT, Kirkpatrick ND, Heishi T, Huang Y, Martin JD, Ager E, Samuel R, Wang S, Yazbek J, Vakoc BJ, Peterson RT, Padera TP, Duda DG, Fukumura D, Jain RK. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. Journal of the National Cancer Institute 2013; 105:1188-201. PubMed
  • Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. 2013; 15:1079-87. PubMed
  • Samuel R, Daheron L, Liao S, Vardam T, Kamoun WS, Batista A, Buecker C, Schäfer R, Han X, Au P, Scadden DT, Duda DG, Fukumura D, Jain RK. Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. Proc Natl Acad Sci U S A 2013; 110:12774-9. PubMed
  • Duda DG, Munn LL, Jain RK. Can We Identify Predictive Biomarkers for Antiangiogenic Therapy of Cancer Using Mathematical Modeling? Journal of the National Cancer Institute 2013. PubMed
  • Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res 2013; 19:1557-66. PubMed
  • Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 2013; 152:1065-76. PubMed
  • Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013. PubMed
  • Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol 2013; 6:51. PubMed
  • Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012; 109:17561-6. PubMed
  • Dima SO, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas 2012; 41:1001-7. PubMed
  • Duda DG, Willett CG. Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? Oncology (Huntingt) 2012; 26:741-3. PubMed
  • Kozin SV, Duda DG, Munn LL, Jain RK. Neovascularization After Irradiation: What is the Source of Newly Formed Vessels in Recurring Tumors? Journal of the National Cancer Institute 2012. PubMed
  • Duyverman AM, Kohno M, Roberge S, Fukumura D, Duda DG, Jain RK. An isolated tumor perfusion model in mice. Nat Protoc 2012; 7:749-55. PubMed
  • Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS ONE 2012; 7:e26331. PubMed
  • Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist 2012; 17:212-9. PubMed
  • Duyverman AM, Kohno M, Duda DG, Jain RK, Fukumura D. A transient parabiosis skin transplantation model in mice. Nat Protoc 2012; 7:763-70. PubMed
  • Duyverman AM, Steller EJ, Fukumura D, Jain RK, Duda DG. Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice. Nat Protoc 2012; 7:756-62. PubMed
  • Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS ONE 2012; 7:e38231. PubMed
  • Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011; 91:1071-121. PubMed
  • Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent M端llerian Carcinoma. 2011; 4:26-33. PubMed
  • Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011. PubMed
  • Hiratsuka S, Goel S, Kamoun WS, Maru Y, Fukumura D, Duda DG, Jain RK. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Natl Acad Sci U S A 2011; 108:3725-30. PubMed
  • Duda DG, Kozin S, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1α) - CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anti-Cancer Therapies? Clin Cancer Res 2011. PubMed
  • Hiratsuka S, Duda DG, Huang Y, Goel S, Sugiyama T, Nagasawa T, Fukumura D, Jain RK. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad Sci U S A 2011; 108:302-7. PubMed
  • Kozin SV, Duda DG, Munn LL, Jain RK. Is vasculogenesis crucial for the regrowth of irradiated tumours? Nat Rev Cancer 2011; 11:532. PubMed
  • Dawson MR, Chae S-S, Jain RK, Duda DG. Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression Am J Cancer Res 2011; 1:144-54.
  • di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 2011; 71:19-28. PubMed
  • Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A 2010. PubMed
  • Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, Delaney TF. Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value. Clin Cancer Res 2010. PubMed
  • Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J. Neurooncol. 2010. PubMed
  • Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 2010; 70:5679-85. PubMed
  • Duda DG, Jain RK. Premetastatic Lung "Niche": Is Vascular Endothelial Growth Factor Receptor 1 Activation Required? Cancer Res 2010; 70:5670-3. PubMed
  • Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28:2817-23. PubMed
  • Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010; 17:206-25. PubMed
  • Duda DG, Ancukiewicz M, Jain RK. Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers? J Clin Oncol 2010; 28:183-5. PubMed
  • Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK. A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer. Oncologist 2010; 15:845-51. PubMed
  • Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 2010; 15:577-83. PubMed
  • Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009; 69:7905-10. PubMed
  • Dawson MR, Duda DG, Fukumura D, Jain RK. VEGFR1-activity-independent metastasis formation. Nature 2009; 461:E4; discussion E5. PubMed
  • Jones R,Capen DE,Jacobson M,Cohen KS,Scadden DT,Duda DG. VEGFR2PDGFRbeta circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI). J Cell Mol Med 2010; 13:3720-9. PubMed
  • Woodward WA,Bristow RG,Clarke MF,Coppes RP,Cristofanilli M,Duda DG,Fike JR,Hambardzumyan D,Hill RP,Jordan CT,Milas L,Pajonk F,Curran WJ,Dicker AP,Chen Y. Radiation Therapy Oncology Group Translational Research Program Stem Cell Symposium: Incorporating Stem Cell Hypotheses into Clinical Trials. Int J Radiat Oncol Biol Phys 2009; 74:1580-91. PubMed
  • Sorensen AG,Batchelor TT,Zhang WT,Chen PJ,Yeo P,Wang M,Jennings D,Wen PY,Lahdenranta J,Ancukiewicz M,di Tomaso E,Duda DG,Jain RK. A "Vascular Normalization Index" as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Cancer Res 2009; 69:5296-300. PubMed
  • Au P,Tam J,Duda DG,Lin PC,Munn LL,Fukumura D,Jain RK. Paradoxical Effects of PDGF-BB Overexpression in Endothelial Cells on Engineered Blood Vessels In Vivo. Am J Pathol 2009; 175:294-302. PubMed
  • Zhu AX,Sahani DV,Duda DG,di Tomaso E,Ancukiewicz M,Catalano OA,Sindhwani V,Blaszkowsky LS,Yoon SS,Lahdenranta J,Bhargava P,Meyerhardt J,Clark JW,Kwak EL,Hezel AF,Miksad R,Abrams TA,Enzinger PC,Fuchs CS,Ryan DP,Jain RK. Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. J Clin Oncol 2009; 27:3027-35. PubMed
  • Willett CG,Duda DG,di Tomaso E,Boucher Y,Ancukiewicz M,Sahani DV,Lahdenranta J,Chung DC,Fischman AJ,Lauwers GY,Shellito P,Czito BG,Wong TZ,Paulson E,Poleski M,Vujaskovic Z,Bentley R,Chen HX,Clark JW,Jain RK. Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study. J Clin Oncol 2009; 27:3020-6. PubMed
  • Jain RK,Duda DG,Willett CG,Sahani DV,Zhu AX,Loeffler JS,Batchelor TT,Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6:327-338. PubMed
  • Kamoun WS,Ley CD,Farrar CT,Duyverman AM,Lahdenranta J,Lacorre DA,Batchelor TT,di Tomaso E,Duda DG,Munn LL,Fukumura D,Sorensen AG,Jain RK. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27:2542-52. PubMed
  • Gerstner ER,Duda DG,di Tomaso E,Ryg PA,Loeffler JS,Sorensen AG,Ivy P,Jain RK,Batchelor TT. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009; 6:229-36. PubMed
  • Perentes JY,Duda DG,Jain RK. Visualizing anti-tumor immune responses in vivo. Dis Model Mech 2009; 2:107-10. PubMed
  • Dawson MR, Duda DG, Chae SS, Fukumura D, Jain RK. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS ONE 2009; 4:e6525. PubMed
  • Tam J,Duda DG,Perentes JY,Quadri RS,Fukumura D,Jain RK. Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells. PLoS ONE 2009; 4:e4974. PubMed
  • Huang P,Duda DG,Jain RK,Fukumura D. Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. Comp Med 2008; 58:253-63. PubMed
  • Au P, Daheron LM, Duda DG, Cohen KS, Tyrrell JA, Lanning RM, Fukumura D, Scadden DT, Jain RK. Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood 2007; 111:1302-5. PubMed
  • Jones RC, Capen DE, Cohen KS, Munn LL, Jain RK, Duda DG. A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents. Nat Protoc 2008; 3:388-97. PubMed
  • Jones RC, Capen D, Petersen B, Jain RK, Duda DG. A protocol for a lung neovascularization model in rodents. Nat Protoc 2008; 3:378-87. PubMed
  • Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT. Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs 2007; 16:1895-908. PubMed
  • Duda DG,Jain RK,Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007; 25:4033-42. PubMed
  • Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK. Targeted therapy in rectal cancer. Oncology (Huntingt) 2007; 21:1055-65; discussion 1065,. PubMed
  • Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8:610-22. PubMed
  • Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007; 13:223-30. PubMed
  • Duda DG. American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer. IDrugs 2007; 10:366-9. PubMed
  • Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwig KA, Jain RK. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol 2007; 4:316-21. PubMed
  • Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95. PubMed
  • Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2007; 2:805-10. PubMed
  • Hagendoorn J,Padera TP,Yock TI,Nielsen GP,di Tomaso E,Duda DG,Delaney TF,Gaissert HA,Pearce J,Rosenberg AE,Jain RK,Ebb DH. Platelet-derived growth factor receptor-beta in Gorham's disease. Nat Clin Pract Oncol 2006; 3:693-7. PubMed
  • Willett CG, Kozin SV, Duda DG, di Tomaso E, Kozak KR, Boucher Y, Jain RK. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 2006; 33:S35-40. PubMed
  • Duda DG. Antiangiogenesis and drug delivery to tumors: bench to bedside and back. Cancer Res 2006; 66:3967-70. PubMed
  • Duda DG, Cohen KS, Kozin SV, Perentes JY, Fukumura D, Scadden DT, Jain RK. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 2005; 107:2774-6. PubMed
  • Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain RK. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 2006; 24:1449-53. PubMed
  • Saito Y,Sunamura M,Motoi F,Abe H,Egawa S,Duda DG,Hoshida T,Fukuyama S,Hamada H,Matsuno S. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther 2005; 13:242-52. PubMed
  • Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A 2006; 103:855-60. PubMed
  • Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3:24-40. PubMed
  • Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23:8136-9. PubMed
  • Jain RK,Au P,Tam J,Duda DG,Fukumura D. Engineering vascularized tissue. Nat Biotechnol 2005; 23:821-3. PubMed
  • Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med 2005; 11:678-82. PubMed
  • Duda DG,Jain RK. Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow. J Clin Invest 2005; 115:596-8. PubMed
  • Duda DG,Fukumura D,Munn LL,Booth MF,Brown EB,Huang P,Seed B,Jain RK. Differential transplantability of tumor-associated stromal cells. Cancer Res 2004; 64:5920-4. PubMed
  • Sunamura M,Lefter LP,Duda DG,Morita R,Inoue H,Yokoyama T,Yatsuoka T,Abe T,Egawa S,Furukawa T,Fukushige S,Oshimura M,Horii A,Matsuno S. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. Pancreas 2004; 28:311-6. PubMed
  • Duda DG,Fukumura D,Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 2004; 10:143-5. PubMed
  • Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7. PubMed
  • Fukumura D,Ushiyama A,Duda DG,Xu L,Tam J,Krishna V,Chatterjee K,Garkavtsev I,Jain RK. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res 2003; 93:e88-97. PubMed
  • Duda DG,Sunamura M,Lefter LP,Furukawa T,Yokoyama T,Yatsuoka T,Abe T,Inoue H,Motoi F,Egawa S,Matsuno S,Horii A. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 2003; 22:6857-64. PubMed
  • Jain RK,Duda DG. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell 2003; 3:515-6. PubMed
  • Sunamura M,Duda DG,Ghattas MH,Lozonschi L,Motoi F,Yamauchi J,Matsuno S,Shibahara S,Abraham NG. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003; 6:15-24. PubMed
  • Hoshida T,Sunamura M,Duda DG,Egawa S,Miyazaki S,Shineha R,Hamada H,Ohtani H,Satomi S,Matsuno S. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 2002; 25:111-21. PubMed
  • Lefter LP,Furukawa T,Sunamura M,Duda DG,Takeda K,Kotobuki N,Oshimura M,Matsuno S,Horii A. Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines. Genes Chromosomes Cancer 2002; 34:234-42. PubMed
  • Duda DG,Sunamura M,Lozonschi L,Yokoyama T,Yatsuoka T,Motoi F,Horii A,Tani K,Asano S,Nakamura Y,Matsuno S. Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis. Br J Cancer 2002; 86:490-6. PubMed
  • Sunamura M,Yatsuoka T,Motoi F,Duda DG,Kimura M,Abe T,Yokoyama T,Inoue H,Oonuma M,Takeda K,Matsuno S. Gene therapy for pancreatic cancer based on genetic characterization of the disease. J Hepatobiliary Pancreat Surg 2002; 9:32-8. PubMed
  • Ding L,Sunamura M,Kodama T,Yamauchi J,Duda DG,Shimamura H,Shibuya K,Takeda K,Matsuno S. In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells. Br J Cancer 2001; 85:431-8. PubMed
  • Sunamura M,Sun L,Lozonschi L,Duda DG,Kodama T,Matsumoto G,Shimamura H,Takeda K,Kobari M,Hamada H,Matsuno S. The antiangiogenesis effect of interleukin 12 during early growth of human pancreatic cancer in SCID mice. Pancreas 2000; 20:227-33. PubMed
  • Duda DG,Sunamura M,Lozonschi L,Kodama T,Egawa S,Matsumoto G,Shimamura H,Shibuya K,Takeda K,Matsuno S. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000; 60:1111-6. PubMed
  • Motoi F,Sunamura M,Ding L,Duda DG,Yoshida Y,Zhang W,Matsuno S,Hamada H. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther 2000; 11:223-35. PubMed
  • Jain RK, Fukumura D, Duda DG. Lessons From 30 Years of Teaching About the Microenvironment of Tumors. Cancer J 2015; 21:137. PubMed
  • Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 2009; 15:263-8. PubMed
Hide